Tolerability and Efficacy of Vortioxetine Versus SSRIs in Elderly with Major Depression. Study Protocol of the Vespa Study: A Pragmatic, Multicentre, Open-Label, Parallel-Group, Superiority, Randomized Trial

CURRENT STATUS: UNDER REVIEW

Giovanni Ostuzzi
Universita degli Studi di Verona

Chiara Gastaldon  chiara.gastaldon@gmail.com
Universita degli Studi di Verona
Corresponding Author
ORCiD: 0000-0001-7257-2962

Angelo Barbato
Istituto di Ricerche Farmacologiche Mario Negri Sede di Milano

Barbara D’Avanzo
Istituto di Ricerche Farmacologiche Mario Negri Sede di Milano

Mauro Tettamanti
Istituto di Ricerche Farmacologiche Mario Negri Sede di Milano

Igor Monti
Istituto di Ricerche Farmacologiche Mario Negri Sede di Milano

Andrea Aguglia
Università degli Studi di Genova

Eugenio Aguglia
Università degli Studi di Catania

Maria Chiara Alessi
Università degli Studi Gabriele d’Annunzio Chieti e Pescara

Mario Amore
Universita degli Studi di Genova
Francesco Bartoli

Universita degli Studi di Milano-Bicocca
Massimo Biondi
Universita degli Studi di Roma La Sapienza Dipartimento di Neurologia e Psichiatria
Paola Bortolaso

Universita degli Studi dell'Insubria
Camilla Callegari

Universita degli Studi dell'Insubria
Giuseppe Carrà
Universita degli Studi di Milano-Bicocca
Rosangela Caruso

Universita degli Studi di Ferrara
Simone Cavallotti
Azienda Ospedaliera San Paolo
Cristina Crocamo

Universita degli Studi di Milano-Bicocca
Armando D’Agostino
Universita degli Studi di Milano Facolta di Medicina e Chirurgia
Pasquale De Fazio
Universita degli Studi Magna Graecia di Catanzaro
Chiara Di Natale
Universita degli Studi Gabriele d'Annunzio Chieti e Pescara
Laura Giusti
Universita degli Studi dell'Aquila

Luigi Grassi
Universita degli Studi di Ferrara
Giovanni Martinotti
Universita degli Studi Gabriele d'Annunzio Chieti e Pescara
Michela Nosé
Universita degli Studi di Verona Scuola di Medicina e Chirurgia
Davide Papola  
Università degli Studi di Verona

Marianna Purgato  
Università degli Studi di Verona

Alessandro Rodolico  
Università degli Studi di Catania

Rita Roncone  
Università degli Studi dell'Aquila

Lorenzo Tarsitani  
Università degli Studi di Roma La Sapienza Facolta di Medicina e Psicologia

Giulia Turrini  
Università degli Studi di Verona

Elisa Zanini  
Università degli Studi di Verona

Francesco Amaddeo  
Università degli Studi di Verona

Mirella Ruggeri  
Università degli Studi di Verona

Corrado Barbui  
Università degli Studi di Verona

DOI: 10.21203/rs.2.19503/v1

SUBJECT AREAS
Integrative & Complementary Medicine   Internal Medicine

KEYWORDS
randomized clinical trial, pragmatic trial, elderly, antidepressants, vortioxetine, depression
Abstract

Introduction. Depression is a highly prevalent condition in the elderly, with a vast impact on quality of life, life expectancy, and medical outcomes. Selective serotonin reuptake inhibitors (SSRIs) are the most commonly prescribed agents in this condition and, although generally safe, tolerability issues cannot be overlooked. Vortioxetine is an antidepressant with a novel mechanism of action. Based on available studies, it may have a promising tolerability profile in the elderly, as it does not adversely affect psychomotor or cognitive performance, and does not alter cardiovascular and endocrine parameters. The present study aims to assess the tolerability profile of vortioxetine in comparison with the SSRIs considered as a single group in elderly participants with depression. The rate of participants withdrawing from treatment due to adverse events after six months of follow-up will be the primary outcome.

Methods and analysis. This is a pragmatic, multicentre, open-label, parallel-group, superiority, randomized trial funded by the Italian Medicines Agency (AIFA - Agenzia Italiana del Farmaco). Thirteen Italian Community Psychiatric Services will consecutively enrol elderly participants suffering from an episode of major depression over a period of 12 months. Participants will be assessed at baseline and after 1, 3 and 6 months of follow-up. At each time point, the following validated rating scales will be administered: Montgomery-Åsberg Depression Rating Scale (MADRS), Antidepressant Side-Effect Checklist (ASEC), EuroQual 5 Dimensions (EQ-5D), Short Blessed Test (SBT), and Charlson Age-Comorbidity Index (CACI). Outcome assessors and the statistician will be masked to treatment allocation. A total of 358 participants (179 in each group) will be enrolled.
Ethics and dissemination. This study will fully adhere to the ICH E6 Guideline for Good Clinical Practice. Participants’ data will be managed and safeguarded according to the European Data Protection Regulation 2016/679. An external Ethical Advisory Board will help guarantee high ethical standards.

Trial registration number. EudraCT number: 2018-001444-66; Clinicaltrials.gov: NCT03779789, first submitted on December 12, 2018 and first posted on December 19th trial status: protocol version 1.5; 09/06/2018. Recruitment started on February 2019 and it is ongoing. It is expected to end approximately on September 30th 2021.

ARTICLE SUMMARY

STRENGTHS AND LIMITATIONS OF THIS STUDY:

-After random allocation, antidepressants and any other pharmacological and non-pharmacological interventions will be managed following everyday clinical practice, aiming to increase external validity and generalizability of results;

-Considering the paucity of evidence on antidepressants for depression in the elderly, and in view of the lack of alternatives to SSRIs in clinical practice, the results of this study may have a significant impact on everyday practice, as well as on regulatory decisions;

-The primary outcome (withdrawing from treatment due to adverse events) cannot be ascertained by masked assessors, however it is highly pragmatic as it closely reflects clinical practice, and its ascertainment will undergo a thorough internal quality check.

INTRODUCTION
Depression is among the most disabling conditions worldwide [1]. It occurs in about 4% of elderly in the community [2] and in up to 49% of persons admitted to nursing homes and hospitals [3 4]. In elderly people, depression is associated with poor quality of life, reduced life expectancy, high risk of suicide [5] and of cognitive decline and dementia [6], reduced adherence to medical treatments and, therefore, poorer medical outcomes [7].

In the general population of individuals with depression, selective serotonin reuptake inhibitor (SSRIs) are considered effective and safe [8]. In the elderly, SSRIs are considered effective and generally safer compared to other classes of antidepressants [9]. Therefore they are recommended by most guidelines as first-choice treatment for older adults [10, 11]. However, the elderly may be particularly vulnerable to adverse events due to aging itself, medical comorbidities, multiple treatments, and high risk of pharmacological interactions [12, 13]. The most common adverse events associated with SSRIs in the elderly include hyponatraemia, postural hypotension, falls, gastrointestinal bleeding, and sexual dysfunctions [14, 15]. Alternatives to SSRIs are lacking in this special population, considering that tricyclic antidepressants (TCAs), serotonin and noradrenaline reuptake inhibitors (SNRIs) and mirtazapine carry a higher risk for a number of adverse events, including sedation, confusion, urinary retention, cardiovascular and gastrointestinal issues [15].

Vortioxetine is a novel antidepressant, licensed for the treatment of depression in 2013 by FDA and EMA [16, 17]. Vortioxetine is an antagonist to 5-HT3, 5-HT1D and 5-HT7 receptors, a partial agonist to the 5-HT1B receptor and a 5-HT1A receptor agonist [18]. Its mechanism of action is not fully understood yet, but it is likely to be related with both a direct modulation of the serotoninergic receptor activity and
an inhibition of the serotonin transporter. Despite similarities with SSRIs, its pharmacological profile is claimed to be novel, and it is classified among “other antidepressants” by the World Health Organization (WHO) ATC/DDD Index 2018 [19]. Vortioxetine has similar pharmacokinetic properties in young and older adults [16], and existing data suggest it should not adversely affect psychomotor or cognitive performance, wakefulness, body weight, and electrocardiogram parameters [20, 21]. Further, possible, beneficial effects on cognition emerged from three randomized trials in participants with cognitive impairment [22]. A recent Cochrane systematic review, which included 15 randomized trials (7746 participants), showed vortioxetine to be effective compared to placebo, while no significant differences emerged between vortioxetine and SNRIs as a class, in terms of both efficacy and tolerability [23]. The review did not include any study comparing vortioxetine with the SSRIs, but a recent network meta-analysis showed that vortioxetine is well tolerated and effective when indirectly compared to SSRIs [8]. Moreover, in two recent randomized trials, vortioxetine did not show significant differences on both mood and cognitive performance when compared to paroxetine [24] and escitalopram [25], respectively. The only available trial conducted in the elderly reported vortioxetine as more effective than placebo in terms of responders (301 participants, relative risk 1.49, 95% CI 1.14 to 1.95), while no differences emerged in terms of tolerability [26].

Aims of the study

The study will assess if, under real-world clinical circumstances, vortioxetine is better tolerated as compared with the SSRIs considered as a group in elderly participants with depression. In addition to tolerability, as secondary outcomes the study will assess acceptability, overall mortality, self-harm and suicide, adverse
events, improvement of depressive symptoms, quality of life, and cognitive performance.

METHODS AND ANALYSIS

This protocol has been reported accordingly to the SPIRIT statements requirements. The complete SPIRIT checklist is available as an additional file and in the table at the end of the manuscript (additional file1).

Study design overview

The VESPA (Vortioxetine in the Elderly vs SSRIs: A Pragmatic Assessment) study is a randomized, parallel-group, multicentre, open-label, pragmatic, superiority trial. Over a 12-month recruitment period, psychiatrists from thirteen Italian Psychiatric Services will consecutively enrol in- and outpatients aged 65 or more suffering from an episode of major depression and requiring treatment with an antidepressant.

Participants will be randomly allocated to vortioxetine or to one of the SSRIs. Apart from treatment allocation, clinicians and patients will be free of increasing or decreasing the dose according to clinical status and circumstances, as well as of stopping or continuing treatment as clinically indicated. Similarly, the use of concomitant medications during the study will be allowed according to clinical status and circumstances. Routine care outside the trial will continue as usual.

During the study, participants will be seen as often as clinically indicated with no extra visits required for the trial. The only requirement will be follow-up visits at one, three, and six months of follow-up (Fig. 1).

As a consequence of these pragmatic characteristics oriented to resemble clinical practice as much as possible, both patients and clinicians will not be blind to pharmacological treatments provided during the trial. Blinding will be applied to
outcome assessors and statisticians performing the analyses. The study has been
designed according to the principles described in the CONSORT statement
(extended version for pragmatic trials) [27] and in agreement with the SPIRIT 2013
statement [28] (see Appendix 1). The study is financially supported by the Italian
Medicines Agency (AIFA - Agenzia Italiana del Farmaco) and has already been
approved by the Ethics Committee for Clinical Research of Verona and Rovigo
(Comitato Etico per la Sperimentazione Clinica delle Province di Verona e Rovigo)
(prot. n. 61211 of the 19/09/2018; Protocol version n. 1.5 of the 09/06/2018).

Assessment of pragmatism

To quantify the level of pragmatism of our study, we employed the pragmatic-
explanatory continuum indicator summary-2 (PRECIS-2) [29]. This is a validated
tool, developed to help investigators make design decisions consistent with the
intended purpose of their trial. It explores nine domains (eligibility criteria,
recruitment, setting, organisation, flexibility (delivery), flexibility (adherence),
follow-up, primary outcome, and primary analysis), for each of which a score from 1
(very explanatory) to 5 (very pragmatic) is provided. The result is graphically
summarized in Fig. 2.

Reasons for the scoring are reported in Table 1. A routine use of the PRECIS-2 tool
when submitting RCT protocols to funders, research ethics committees and peer-
reviewed journals, has been growingly recommended, considering that not all RCTs
self-labelled as "pragmatic" or "naturalistic" are actually pragmatic. This process
can also help understand the extent to which trial results may be relevant to real-
world practice [30].

Table 1. Scoring of PRECIS-2 tool. PRECIS 5-point Likert Scale score: (1) Very
Explanatory; (2) Rather Explanatory; (3) Equally Pragmatic/Explanatory; (4) Rather
Pragmatic; (5) Very Pragmatic.

| Items                                                                 | Score | Rationale                                                                                                                                                                                                 |
|----------------------------------------------------------------------|-------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Eligibility - to what extent are the participants in the trial similar to those who would receive this intervention if it was part of usual care? | 4     | Target population: Elderly with depression. Inclusion criteria are wide. No exclusion criteria will be applied in terms of setting of recruitment, severity of depression, past use of psychotropic drugs, current use of benzodiazepines, number and severity of medical comorbidities, and multiple pharmacotherapy. Diagnosis are based on clinical judgment (guided by DSM-5 criteria), as it is in usual practice. Nevertheless investigator and patient have to agree to discontinue any current antidepressant, second generation antipsychotic, or lithium. |
| Recruitment - how much extra effort is made to recruit participants over and above what that would be used in the usual care setting to engage with patients? | 5     | Participants will be recruited without extra efforts. They will be recruited during usual appointments and/or visits.                                                                                   |
| Setting - how different is the setting of the trial and the usual care setting? | 4     | The study is multicenter, based in more than 10 psychiatric centers of the National Health System in Italy with a University center.                                                                  |
| Organisation - how different are the resources, provider expertise and the organisation of care delivery in the intervention arm of the trial and those available in usual care? | 4     | We will use usual staff and resources, but some extra resources will be necessary to hire researchers for the study.                                                                                   |
| Flexibility (delivery) - how different is the flexibility in how the intervention is delivered and the flexibility likely in usual care? | 5     | The intervention is flexible, similar to usual care.                                                                                                                                                     |
| Flexibility (adherence) - how different is the flexibility in how participants must adhere to the intervention and the flexibility likely in usual care? | 4     | No extra measures. Participants will be free to assume the intervention or drop it, but drugs will be prescribed and given to the participants during visits. This is different from usual care (patients have a prescription and go to the pharmacy to buy drugs). |
| Follow-up - how different is the intensity of measurement and follow-up of participants in the trial and the likely follow-up in usual care? | 4     | The primary outcome will be assessed after 1, 3 and 6 months, as it is usually done in everyday practice. Six months represent a clinically sound time frame for assessing the overall tolerability of medications, including both acute, short-term and medium-long-term effects. Nevertheless, visits could be longer than usual to assess all the scales and long-term effects and adverse events could occur after 6 months. |
| Primary outcome - to what extent is the trial's primary outcome relevant to participants? | 5     | Primary outcome is relevant to participants and policy makers.                                                                                                                                          |
| Primary analysis - to what extent is the Intention to Treat (ITT) | 5     | The Intention to Treat (ITT)                                                                                                                                                                             |
Participants

The following inclusion criteria will be applied:

a. The participant is 65 years old or above;
b. The participant is willing to participate by signing an informed consent form;
c. The participant is suffering from an episode of major depression, based on clinical judgment (guided by DSM-5 criteria);
d. Treatment with an antidepressant is appropriate, based on clinical judgment;
e. There is agreement between investigator and participant to discontinue any of the following concomitant drugs: antidepressant, second generation antipsychotic, or lithium. All other concomitant medications are allowed;
f. Uncertainty about which trial treatment would be best for the participant.

Participants will be excluded in case of:

a. Dementia, of any type and stage, as formally diagnosed by a specialist (geriatrician, neurologist, or others);
b. Diagnosis of schizophrenia or bipolar disorder;
c. Clinical conditions or treatments that contraindicate the use of oral vortioxetine or SSRIs, according to clinical/medical judgment (for example conditions or treatments that increase risk of bleeding, seizures, serotoninergic syndrome, hyponatraemia, etc.).

All medications will be prescribed according to routine clinical practice, in compliance with the Summary of Product Characteristics (SPC) registered in the AIFA databank (https://farmaci.agenziafarmaco.gov.it/bancadatifornacil/home).
No exclusion criteria will be applied in terms of setting of recruitment, severity of depression, past use of psychotropic drugs, current use of benzodiazepines (as long as SPC indications are respected), number and severity of medical comorbidities, and multiple pharmacotherapy. Such criteria will select participants similar to those who require antidepressant treatment under usual care, including patients with multiple medical comorbidities. The recruitment will be pragmatic, as participants will be selected among people attending inpatient and outpatient community services. There will not be overt recruitment effort. Also, allowing different recruitment settings, having multiple sites of recruitment, and selecting patients similar to those who are treated in every day clinical practice, will increase the generalizability of trial results. To control for a potential risk of excessive heterogeneity between centres, the randomization will be stratified by centre. According to these features, the PRECIS-2 “setting” domain has been evaluated as pragmatic.

Interventions
Patients will be randomized to either vortioxetine or one of the SSRIs. Doctors will be free to choose which SSRIs is more appropriate among those marketed in Italy and commonly used in clinical practice in the elderly (sertraline, citalopram, escitalopram, paroxetine, fluoxetine, fluvoxamine). A flexible dosing schedule, within the licensed dose range and in line with the summary of product characteristics (SPC), will be suggested (Table 2) in order to resemble clinical practice as much as possible.

Table 2. Treatments and dosing schedule
| Medication | Licensed dose range in the elderly | Notes from the registered Summary of Product Characteristics |
|------------|-----------------------------------|---------------------------------------------------------------|
| vortioxetine | 5–20 mg/day | The minimum effective dose of 5 mg vortioxetine once daily should always be used as an initial dose for participants aged ≥ 65 years. Caution should be exerted when prescribing to elderly participants at doses above 10 mg vortioxetine once daily. |
| sertraline | 50–200 mg/day | Caution is required in the elderly, because these patients may be at greater risk of hyponatraemia. |
| paroxetine | 20–40 mg/day | In the elderly, increased plasma concentrations of paroxetine have been reported, however within the range observed in younger subjects. The treatment should start at the same doses used in adults. |
| citalopram | 10–20 mg/day | In the elderly, half of the dose range prescribed in adults is required. |
| escitalopram | 5–10 mg/day | In the elderly, half of the dose range prescribed in adults is required. |
| fluoxetine | 20–60 mg/day | Caution is required when the dose is increased in the elderly, and generally the daily dose should not be above 40 mg/day. The maximum recommended dose is 60 mg/day. |
| fluvoxamine | 100–300 mg/day | In elderly participants, titration should be slower and the dosage should always be established with caution. |

Formulation choice (tablets versus drops) will be made by clinicians and participants following every day practice, and no measures will be implemented to optimise treatment adherence.

According to the PRECIS-2 “flexibility-delivery” and “flexibility-adherence” domains, treatment delivery has been rated as pragmatic, although a full score of 5 could not be reached as we were formally required to follow the EU pharmacovigilance regulation [31, 32].

Outcome measures

The number of participants withdrawing from allocated treatment due to adverse events at the end of the study (6 months) will represent the primary outcome. This measure may be considered a pragmatic proxy of tolerability [33] as it occurs when
adverse events actually reach an unbearable burden, as perceived by patients and/or relatives and/or carers and/or clinicians. Antidepressant treatment will be considered withdrawn due to adverse effects when the drug is stopped for more than two consecutive weeks following the occurrence of any adverse event, based on clinical judgment and/or as reported by participants. Participants will be additionally evaluated after also one and three months from randomization, collecting relevant clinical information and assessing scales, as showed in table 3. Side effects responsible for treatment withdrawal, and their severity, will be recorded the follow-up form and an ad hoc form for Severe Adverse Events (SAE).

Secondary outcomes will include:

1. acceptability: withdrawals from allocated treatment due to any cause (this outcome measure will include withdrawals for side-effects plus withdrawals for any other issues);

2. overall mortality;

3. any episode of deliberate self-harm;

4. suicide mortality;

5. adverse events, measured as the mean change in scores at the Antidepressant Side-Effect Checklist (ASEC) [34] at each time point. ASEC is a validated rating scale measuring the occurrence and severity of 21 antidepressant adverse events;

6. response to treatment, defined as a reduction of at least 50% of the baseline score of the Montgomery-Åsberg Depression Rating Scale (MADRS) [35] at each time point. MADRS is a validated, ten-item questionnaire for assessing the severity of depression;

7. efficacy, measured as mean change scores at MADRS at each time point;
8. quality of life, measured as mean change scores of the self-administered scale EQ-5D,[36], at each time point. EQ-5D explores five areas, including mobility, self-care, usual activities, pain/discomfort, anxiety/depression, and assesses the overall subjective perception of health with an analogic scale;

9. cognitive performance, measured as mean change scores of the Short Blessed Scale (SBT) [37], at each time point. SBT is a validated, six-item weighted instrument, originally designed to identify dementia, which assesses orientation, registration, and attention.

Rating scales to assess the secondary outcomes will be administered by blind assessors at one, two and three months after randomization. In addition, the Charlson Age-Comorbidity Index (CACI) [38] will be employed. This is a validated rating scale used to evaluate the degree of medical comorbidity, and to predict the 10-year survival in participants with multiple comorbidities. All study tools and phases are shown in Table 3.

Table 3. Study phases and tools

| Procedures and tools                      | T0 Enrolment phase (duration: 12 months) | T1 (1 month) | T2 (3 months) | T3 (6 months) |
|-------------------------------------------|------------------------------------------|--------------|---------------|---------------|
| Review of criteria for inclusion in the study | X                                        |              |               |               |
| Informed consent document signed          | X                                        |              |               |               |
| Randomization (allocation to treatment and number assigned) | X                                        |              |               |               |
| Recruitment Form                          | X                                        |              |               |               |
| ASEC                                      | X                                        | X            | X             |               |
| MADRS                                     | X                                        | X            | X             | X             |
| EQ-5D                                     | X                                        | X            | X             | X             |
| CACI                                      | X                                        | X            | X             |               |
| SBT                                       | X                                        | X            | X             |               |
| Follow-up form                            | X                                        | X            |               |               |
| Severe Adverse Event (SAE) Form           | Any time (Any time)                      |              |               |               |

Safety
The VESPA study will operatively employ the definitions endorsed by the EC Directive 2001/20/EC,[39]. As soon as a severe adverse event occurs, an ad hoc form for Severe Adverse Events (SAE) will be filled in and forwarded to the coordinating centre (University of Verona), in accordance with the EU regulation about pharmacovigilance in clinical research [31]. If, for any reasons, the disadvantages of participation will appear to be significantly greater than foreseen, the Principal Investigator of the site will inform trial participants and the bodies providing ethical oversight.

Considering that the study medications are already in the Italian market, and considering that they will be prescribed for licensed indications without altering clinical practice, the VESPA study has not appointed an ad hoc data safety and monitoring committee.

Randomization
Participants will be randomly assigned to vortioxetine or SSRIs with an allocation ratio of 1:1. A centralized web-based randomization procedure will be employed to guarantee the concealment of allocation. The trial biostatistician will prepare the sequence of treatments randomly permuted in blocks of constant size. The site investigators will not know the block size. Allocation will be stratified by recruiting centre. By using the web-based application RedCap [40], investigators will be able to screen participants for inclusion, administer instruments maintaining the blindness to treatment allocation, and randomize them.

Data management
At baseline, before randomization, and after one, three and six months, a number of socio-demographic and clinical information will be collected, along with the administration of the above-mentioned validated rating scales (MADRS, EQ-5D,
CACI, SBT, ASEC). All data on other medications will be registered at every visit. The ASEC scale will be administered only during follow-up.

All study data will be collected with RedCap and digitally stored by the Istituto di Ricerche Farmacologiche Mario Negri IRCCS, a not-for-profit biomedical research organization based in Milan (Italy), where also the statistical analysis will be performed. RedCap will allow an immediate data validation at the moment of data collection. Moreover, a set of electronic and manual edit checks will be performed. The local coordinator of each recruiting centre will store and safely preserve hard copy documents (signed informed consent and self-administered questionnaires) for at least 7 years after the end of the study, according to the Italian law. At the end of the study the full dataset will be made available upon motivated request as a spreadsheet file in an online repository (e.g. Dryad Digital Repository). This is in line with FAIR principles [41], aimed at enhancing the accessibility and reutilization of novel research data.

The accuracy and completeness of data collection will be monitored by site visits. At least one visit for each recruiting centre is planned. Furthermore, auditing will be also carried out remotely, as the data manager of the study will be able to regularly check the trial dataset through the web application RedCap.

Power analysis

Considering the differential rate of withdrawals due to adverse events between SSRIs and vortioxetine on the basis of a meta-analysis of antidepressants for older people [9] and of three clinical trials of vortioxetine in older patients with depression [21, 26, 42] we expect the vortioxetine group to show a clinically significant advantage by reducing this rate from about 17% [9] to about 5% [21, 26, 42]. A sample size of 276 participants (138 in each group) achieves 90% power to
detect a difference of 12% between the two withdrawal proportions in favour of vortioxetine. The test statistics will be the two-sided Z test with pooled variance. The significance level of the test is targeted at 5%. On the basis of the above-mentioned studies, we can assume that about 23% of the participants could be lost within 6 months (the mean of the total dropout rates of vortioxetine and SSRI studies in the elderly). Therefore 358 participants (179 in each group) will be enrolled in order to obtain at least 276 evaluable subjects. The sample size calculation was performed according to the methodology described by Pocock [43].

Statistical Analysis

According to the pragmatic principle of intention-to-treat (ITT), efforts will be made to follow each participant until the end of the study. The ITT population will consist of all randomized participants, and will be used for the analysis of both primary and secondary outcomes. The absolute risk of the primary outcome will be calculated on the ITT population. Subjects with missing primary outcome data will be allocated to the worst outcome. When possible, in addition to the primary analysis, appropriate statistical methods will adjust for the potential confounding effect of prognostic factors (sex, age, living condition, severity of comorbid medical conditions, previous psychiatric history, MADRS score at baseline). Missing rating scales scores will be imputed using the Last Observation Carried forward (LOCF) approach: ratings will be carried forward from the last available assessment to the 6-month follow-up assessment. As a secondary analysis, missing scores will be imputed following a multiple imputation approach [44].

In order to check the results of the ITT approach, though for confirmatory purposes only, the primary outcome will also be analysed using a per-protocol (PP) approach. According to the PP approach, analysis will be restricted to subjects with primary
outcome assessment available at six-months. Subjects withdrawing for reasons not related to adverse effects will be excluded from the analysis.

The proportion of participants withdrawing from the study due to adverse events within 6 months of follow-up will be compared between the two groups of treatment using a logistic regression with centre (random variable) as a covariate. A multivariable analysis (secondary analysis) will be performed through a Poisson regression model with a robust error variance, given that this procedure allows to estimate relative risks directly [45].

For dichotomous secondary outcomes, the proportion of participants withdrawing from the study due to adverse events within 6 months will be compared between the two groups of treatment using a logistic regression with centre (random variable) as a covariate. When possible, a multivariable analysis will be performed through a Poisson regression model with a robust error variance. For continuous secondary outcomes, the 6-month estimate will be compared between the two groups of treatment with an analysis of covariance with baseline value as an additional covariate, or with Mann-Whitney test on changes, according to the variable’s distribution. Same outcomes will be studied using linear mixed models taking into account all assessments to evaluate the rate of change with shorter repeated evaluations and no need of missing imputation. Further, score changes in subscales will be evaluated in order to detect possible specific treatment-related side-effects.

A Cox proportional hazard model will be used to explore time to treatment withdrawal due to adverse events (secondary analysis). The proportional hazard assumption of the effects will be tested.

Adverse events will be tabulated. Nominal value for statistical significance will be
set at 0.05, two-tailed. A specific Statistical Analysis Protocol will be produced and made publicly available before the inclusion of the last participant. All analyses will be performed using STATA [46], release 15 or higher.

ETHICS AND DISSEMINATION

This study will be conducted according to globally accepted standards of good clinical practice, as defined in the ICH E6 Guideline for Good Clinical Practice, 1 May 1996, in agreement with the Declaration of Helsinki [47] and in keeping with local regulations. The recruiting investigators will obtain informed consent. All participants will be informed about the study procedures and aims, both verbally and by written documentation. The subject’s consent will be confirmed by the personally dated signature of the subject and by the personally dated signature of the person conducting the informed consent discussion. Participants can withdraw from the study at any time without further explanation or any negative consequences. Participants’ data will be managed and safeguarded in accordance with the European Data Protection Regulation 2016/679 [48]. The highly pragmatic design will minimize the time deduction to ordinary clinical practice. An Ethics Advisory Board (EAB) will indirectly supervise the processes of recruitment, informed consent procedures, and data management (protection and privacy), taking into due account the vulnerability of the population. Once the final report will be available, the study results will be extensively disseminated to the international scientific community in the form of peer-reviewed journal articles, giving preference to open-access journals.

The study is financially supported by the AIFA and has already been approved by the Ethics Committee for Clinical Research of Verona and Rovigo (Comitato Etico per
Discussion

The design of this study aims at achieving a high level of pragmatism. This approach will allow to minimize the risk of selection bias (particularly relevant when assessing frail populations such as the elderly, often excluded from experimental research), to resemble routine clinical procedures as much as possible, and therefore to maximize the external validity and generalizability of results [49].

Firstly, participants will be enrolled on the basis of the need for an antidepressant prescription because of a depressive episode. No formal diagnostic assessment will be performed, as happens in clinical practice. No limitations to the recruitment setting will be applied. Rating scales will be easy to administer and of relatively short duration, in order not to substantially alter clinical practice. Secondly, a web-based application will allow to simplify the process of recruitment, randomization, and collection of socio-demographic and clinical data, minimizing the time deducted from ordinary clinical practice. Thirdly, the comparison group will consist of participants receiving any of the SSRIs. We made this choice in order to avoid the possibility of selection bias, that is to avoid the systematic exclusion of participants who did not benefit from a specific SSRI in the past. Furthermore, flexible dosing schedule will be employed, according to clinical judgment, within the recommended therapeutic range.

Some limitations need to be outlined. Firstly, according to the current pharmacovigilance regulation of the European Union, medication boxes must be labelled and dispensed by the hospital pharmacy. This deviates from ordinary
practice, and may have an impact on adherence to medications. Secondly, in order to avoid the potential confounding effect of other psychotropic drugs, to be included in the trial patients have to discontinue any other antidepressant or second generation antipsychotic before random allocation, but after random allocation any concomitant medication will be allowed. Again, this choice aims at resembling everyday practice, as elderly patients are sometimes prescribed low doses of second generation antipsychotics or antidepressant (e.g. mirtazapine, amitriptyline, trazodone) for insomnia or for other symptoms (e.g. cachexia, cephalalgia, etc.).

Thirdly, the open-label design might be associated with a risk of performance bias. Theoretically, it may be possible that clinicians, being aware of the treatments received by participants, perform differently according to the allocated treatment arms, based on personal subjective judgments. For example, they may provide vortioxetine, or the control SSRI, at excessively low or high doses, altering this way the likelihood of dropping out from treatment because of side-effects or lack of efficacy. Although we cannot completely rule out this possibility, we note the following. First, as both treatment arms involve active antidepressants, it seems unlikely that doctors involved in the study, working in very diverse settings across Italy, share similar a-priori opinions and, based on these opinions, systematically favour or disfavour either vortioxetine or the control SSRIs. Second, any dose changes and any use of concomitant medicines, as well as any provision of additional non-pharmacological treatments, will be recorded, which is important to investigate if, apart from the study medications, the two groups were treated similarly. Third, blinded assessors will independently assess the presence and severity of adverse events using the ASEC, and this will allow an internal quality check of the accuracy of the primary outcome.
Considering the overall psychological, medical and economic burden of depression in the elderly, and the few available pharmacological alternatives for treating this population group, the results of this study are likely to have a positive impact on everyday clinical practice. Furthermore, considering the pragmatic nature of the study, we expect that results will be immediately applicable to ordinary practice without requiring any specific training or implementation strategies. If the hypothesis of a better tolerability of vortioxetine is confirmed, this drug may become a reference first-line drug for the treatment of depression in the elderly. This, besides improving the overall psychological well-being and quality of life of elderly people with depression, might at the same time reduce hospitalizations for medical adverse events (such as falls, bleeding, hyponatraemia, QTc alterations), poor medical outcomes, and related health care costs. If, on the other hand, vortioxetine is not better tolerated than SSRIs, its place in the treatment of the elderly will be clearer, and the VESPA study results will be used to better inform clinical and policy practice.

Additionally, this study may have regulatory implications, considering that, currently, according to the EMA, “caution is advised when treating participants ≥ 65 years of age with doses higher than 10 mg vortioxetine once daily for which data are limited” [17, 18]. We expect that this statement may be reformulated in view of the study results: if vortioxetine is better tolerated than the SSRIs, by mentioning its favourable tolerability profile; if vortioxetine is less tolerated than the SSRIs, by further reinforcing the cautionary statement.

**Abbreviations**

selective serotonin reuptake inhibitor (SSRIs), Randomized controlled trial (RCT),
tricyclic antidepressants (TCAs), serotonin and norepinephrine reuptake inhibitors
(SNRIs), Food and Drug administration (FDA), European Medicine Agency (EMA),
World Health Organization (WHO), Vortioxetine in the Elderly vs SSRI: A Pragmatic
Assessment (VESPA), Italian Medicines Agency (AIFA - Agenzia Italiana del Farmaco),
Pragmatic-explanatory continuum indicator summary-2 (PRECIS-2), Summary of
Product Characteristics (SPC), Severe Adverse Events (SAE), Antidepressant Side-
Effect Checklist (ASEC), Montgomery-Åsberg Depression Rating Scale (MADRS),
Short Blessed Scale (SBT), Charlson Age-Comorbidity Index (CACI), Intention-to-treat
(ITT), Last Observation Carried forward (LOCF), per-protocol (PP), Ethics Advisory
Board (EAB).

Declarations

**Trial Status:** protocol version 1.5; 09/06/2018. Recruitment started on February
2019 and it is ongoing. It is expected to end approximately on September 30th
2021.

**Ethics approval and consent to participate**

The protocol (version 1.5; 09/06/2018) has already been approved by the Ethics
Committee for Clinical Research of Verona and Rovigo (approval reference number:
Prot n. 61211 19/09/2018). All participants will sign a written informed consent
form.

**Availability of data and materials**

At the end of the study the full dataset will be made available upon motivated
request as a spreadsheet file in an online repository (e.g. Dryad Digital Repository).
This is in line with FAIR principles [41], aimed at enhancing the accessibility and
reutilization of novel research data.
Competing interests

The authors have no competing interests to disclose.

Funding

The study is funded by AIFA within the 2016 call for Independent Research on Drugs (Bando AIFA per la Ricerca Indipendente 2016); code: 2016-0234923. The study sponsor will have no role in study design; in the collection, management, analysis, and interpretation of data; in writing the report; and in the decision to submit the report for publication. The study sponsor has no ultimate authority over any of the listed activities.

Consent to publication

N/A. Not applicable.

Authors' contributions

All authors listed have made substantial contributions to the design of the study; contributed to draft and revising the manuscript, approving the final version to be published. All authors agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Designed the study: GO, CB, AB, BDA, MT; drafted the manuscript: GO, CB, AB, BDA, MT, CG; development and implementation on the online tool for data collection: IM; contributed to the design of the study and its in-field implementation via plenary meetings, revised and approved the manuscript: CG, AA, EA, CA, MA, FB, MB, PB, CC, GC, RC, SC, CCr, ADA, PDF, CDN, LG, LGDr, GM, MN, DP, MP, AR, RR, LT, GT, EZ, FA, MR.

Acknowledgements

None.
References

1. GBD. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 2016;388(10053):1659-724 doi: 10.1016/s0140-6736(16)31679-8 [published Online First: Epub Date]].

2. CDCP. Current depression among adults-United States, 2006 and 2008. Centers for Disease Control and Prevention Morbidity and mortality weekly report 2010;59(38):1229-35

3. Ames D. Depression among elderly residents of local-authority residential homes. Its nature and the efficacy of intervention. Br J Psychiatry 1990;156:667-75

4. Eden J. Institute of medicine. The mental health and substance use workforce for older adults. In whose hands? . Washington D.C.: National Academies Press., 2012. https://doi.org/10.17226/13400

5. Heisel MJG; Moore S L; Jackson F. et al. National Guidelines for Seniors’ Mental Health: The Assessment of Suicide Risk and Prevention of Suicide. Can Geriatr J 2006; 9(2):s65-s70

6. Steenland K, Karnes C, Seals R, et al. Late-life depression as a risk factor for mild cognitive impairment or Alzheimer's disease in 30 US Alzheimer's disease centers. J Alzheimers Dis 2012;31(2):265-75 doi: 10.3233/jad-2012-111922 [published Online First: Epub Date]].

7. Jiang W, Alexander J, Christopher E, et al. Relationship of depression to increased risk of mortality and rehospitalization in patients with congestive
heart failure. Arch Intern Med 2001;161(15):1849-56

8. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet 2018;391(10128):1357-66 doi: 10.1016/s0140-6736(17)32802-7[published Online First: Epub Date]].

9. Mottram P, Wilson K, Strobl J. Antidepressants for depressed elderly. Cochrane Database Syst Rev 2006 (1): Cd003491 doi: 10.1002/14651858.CD003491.pub2 [published Online First: Epub Date]].

10. National Institute for Health and Care Excellence. Depression in adults: recognition and management [Internet]. [London]: NICE; 2009 [updated 2016 Apr; cited 2016 Dec 16]. (Clinical guideline [CG90]). Available from: https://www.nice.org.uk/guidance/cg90

11. Avasthi A, Grover S. Clinical Practice Guidelines for Management of Depression in Elderly. Indian J Soc Psychiatry 2018;60(Suppl 3): S341-s62 doi: 10.4103/0019-5545.224474 [published Online First: Epub Date]].

12. Taylor WD. Should antidepressant medication be used in the elderly? Expert Rev Neurother 2015;15(9):961-3 doi: 10.1586/14737175.2015.1070671 [published Online First: Epub Date]].

13. Sultana J, Spina E, Trifiro G. Antidepressant use in the elderly: the role of pharmacodynamics and pharmacokinetics in drug safety. Expert Opin Drug Metab Toxicol 2015;11(6):883-92 doi: 10.1517/17425255.2015.1021684[published Online First: Epub Date]].

14. de Abajo FJ. Effects of selective serotonin reuptake inhibitors on platelet function: mechanisms, clinical outcomes and implications for use in elderly
patients. Drugs Aging 2011;28(5):345-67 doi: 10.2165/11589340-000000000-00000 [published Online First: Epub Date]]

15. Hickie IB. Antidepressants in elderly people. BMJ 2011;343:d4660 doi: 10.1136/bmj.d4660 [published Online First: Epub Date]]

16. FDA. Drug Approval Package. Brintellix (vortioxetine) Tablets. Company: Takeda Pharmaceuticals USA, Inc.; Application No.: 204447. Food and Drug Administration. 2013.
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204447Orig1s000TOC.cfm (accessed 13 May 2019)

17. EMA. Brintellix. Vortioxetine. Procedure No. EMEA/H/C/002717. Applicant: H. Lundbeck A/S. Assessment report for an initial marketing authorisation application. European Medicines Agency. 2013.
https://www.ema.europa.eu/en/documents/assessment-report/brintellix-epar-public-assessment-report_en.pdf

18. EMA. Brintellix : EPAR - Product Information. Brintellix -EMEA/H/C/002717 - IB/0020. European Medicines Agency 2014.
http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002717/WC500159449.pdf.

19. Methodology WCCfDS. ATC classification index with DDDs. Oslo, Norway, 2019.
https://www.whocc.no/atc_ddd_index/

20. Kelliny M, Croarkin PE, Moore KM, et al. Profile of vortioxetine in the treatment of major depressive disorder: an overview of the primary and secondary literature. Ther Clin Risk Manag 2015;11:1193-212 doi: 10.2147/tcrm.S55313[published Online First: Epub Date]]

21. McIntyre RS, Lophaven S, Olsen CK. A randomized, double-blind, placebo-
controlled study of vortioxetine on cognitive function in depressed adults. Int J Neuropsychopharmacol 2014;17(10):1557-67 doi: 10.1017/s1461145714000546[published Online First: Epub Date]].

22. Miskowiak KW, Ott CV, Petersen JZ, et al. Systematic review of randomized controlled trials of candidate treatments for cognitive impairment in depression and methodological challenges in the field. European neuropsychopharmacology : the journal of the Eur Neuropsychopharmacol 2016;26(12):1845-67 doi: 10.1016/j.euroneuro.2016.09.641[published Online First: Epub Date]].

23. Koesters M, Ostuzzi G, Guaiana G, et al. Vortioxetine for depression in adults. The Cochrane Database Syst Rev 2017;7:Cd011520 doi: 10.1002/14651858.CD011520.pub2[published Online First: Epub Date]].

24. Baune BT, Sluth LB, Olsen CK. The effects of vortioxetine on cognitive performance in working patients with major depressive disorder: A short-term, randomized, double-blind, exploratory study. J Affect Disord 2018;229:421-28 doi: 10.1016/j.jad.2017.12.056[published Online First: Epub Date]].

25. Vieta E, Sluth LB, Olsen CK. The effects of vortioxetine on cognitive dysfunction in patients with inadequate response to current antidepressants in major depressive disorder: A short-term, randomized, double-blind, exploratory study versus escitalopram. J Affect Disord 2018;227:803-09 doi: 10.1016/j.jad.2017.11.053[published Online First: Epub Date]].

26. Katona C, Hansen T, Olsen CK. A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder. Int Clin Psychopharmacol 2012;27(4):215-23 doi: 10.1097/YIC.0b013e3283542457
27. Zwarenstein M, Treweek S, Gagnier JJ, et al. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ 2008;337:a2390 doi: 10.1136/bmj.a2390
28. Chan AW, Tetzlaff JM, Altman DG, et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med 2013;158(3):200-7 doi: 10.7326/0003-4819-158-3-201302050-00583
29. Loudon K, Treweek S, Sullivan F, et al. The PRECIS-2 tool: designing trials that are fit for purpose. BMJ 2015;350:h2147 doi: 10.1136/bmj.h2147
30. Dal-Re R, Janiaud P, Ioannidis JPA. Real-world evidence: How pragmatic are randomized controlled trials labeled as pragmatic? BMC Med 2018;16(1):49 doi: 10.1186/s12916-018-1038-2
31. EU. DIRECTIVE 2010/84/EU OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 15 December 2010 amending, as regards pharmacovigilance, Directive 2001/83/EC on the Community code relating to medicinal products for human use. Official Journal of the European Communities 2010;348:74-99
32. EU. Communication from the Commission — Detailed guidance on the collection, verification and presentation of adverse event/reaction reports arising from clinical trials on medicinal products for human use (‘CT-3’). Official Journal of the European Union 2011;2011/C(172):1-13
33. Barbui C, Furukawa TA, Cipriani A. Effectiveness of paroxetine in the treatment of acute major depression in adults: a systematic re-examination of published and unpublished data from randomized trials. CMAJ 2008;178(3):296-305 doi:
34. Uher R, Farmer A, Henigsberg N, et al. Adverse reactions to antidepressants. Br J Psychiatry 2009;195(3):202-10 doi: 10.1192/bjp.bp.108.061960 [published Online First: Epub Date]].

35. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-9

36. EuroQol. EuroQol--a new facility for the measurement of health-related quality of life. Health Policy 1990;16(3):199-208

37. Katzman R, Brown T, Fuld P, et al. Validation of a short Orientation-Memory-Concentration Test of cognitive impairment. Am J Psychiatry 1983;140(6):734-9 doi: 10.1176/ajp.140.6.734 [published Online First: Epub Date]].

38. Charlson M, Szatrowski TP, Peterson J, et al. Validation of a combined comorbidity index. J Clin Epidemiol 1994;47(11):1245-51

39. EU. Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use, 2001. https://ec.europa.eu/health/sites/health/files/files/eudralex/vol-1/dir_2001_20/dir_2001_20_en.pdf (accessed 13 May 2019)

40. Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009;42(2):377-81 doi: 10.1016/j.jbi.2008.08.010 [published Online First: Epub Date]].

41. Wilkinson MD, Dumontier M, Aalbersberg IJ, et al. The FAIR Guiding Principles for scientific data management and stewardship. Sci Data 2016;3:160018 doi:
10.1038/sdata.2016.18[published Online First: Epub Date]].

42. Mahableshwarkar AR, Zajecka J, Jacobson W, et al. A Randomized, Placebo-Controlled, Active-Reference, Double-Blind, Flexible-Dose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive Disorder. Neuropsychopharmacology 2016;41(12):2961 doi: 10.1038/npp.2016.181[published Online First: Epub Date]].

43. Pocock SJ. Clinical trials. A practical approach. Chichester: Wiley, 1983.

44. Little RJ, D'Agostino R, Cohen ML, et al. The prevention and treatment of missing data in clinical trials. N Engl J Med 2012;367(14):1355-60 doi: 10.1056/NEJMsr1203730[published Online First: Epub Date]].

45. Zou G. A modified poisson regression approach to prospective studies with binary data. Am J Epidemiol 2004;159(7):702-6

46. Stata Statistical Software: Release 15 [program]. College Station, TX: StataCorp LLC, 2017.

47. WMA. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. Jama 2013;310(20):2191-4 doi: 10.1001/jama.2013.281053[published Online First: Epub Date]].

48. EU. REGULATION (EU) 2016/679 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 27 April 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data, and repealing Directive 95/46/EC (General Data Protection Regulation). Official Journal of the European Union 2016;119:1-88

49. Ford I, Norrie J. Pragmatic Trials. N Engl J Med 2016;375(5):454-63 doi: 10.1056/NEJMra1510059[published Online First: Epub Date]].
Table 4

Due to technical limitations, Table 4 is provided in the Supplementary Files.

Figures
Figure 1

Study flow-chart. Legend: RF=recruitment form; FUF=follow-up form; MADRS=MoI
Figure 2

Pragmatism wheel according to the PRECIS-2 tool

Supplementary Files

This is a list of supplementary files associated with the primary manuscript. Click to download.

Table 4.docx
Additional file 1.doc

INTRODUCTION

Depression is among the most disabling conditions worldwide [1]. It occurs in about 4% of elderly in the community [2] and in up to 49% of persons admitted to nursing homes and hospitals [3 4]. In elderly people, depression is associated with poor quality of life, reduced life expectancy, high risk of suicide [5] and of cognitive decline and dementia [6], reduced adherence to medical treatments and, therefore, poorer medical outcomes [7].
In the general population of individuals with depression, selective serotonin reuptake inhibitor (SSRIs) are considered effective and safe [8]. In the elderly, SSRIs are considered effective and generally safer compared to other classes of antidepressants [9]. Therefore they are recommended by most guidelines as first-choice treatment for older adults [10, 11]. However, the elderly may be particularly vulnerable to adverse events due to aging itself, medical comorbidities, multiple treatments, and high risk of pharmacological interactions [12, 13]. The most common adverse events associated with SSRIs in the elderly include hyponatraemia, postural hypotension, falls, gastrointestinal bleeding, and sexual dysfunctions [14, 15].

Alternatives to SSRIs are lacking in this special population, considering that tricyclic antidepressants (TCAs), serotonin and norepinephrine reuptake inhibitors (SNRIs) and mirtazapine carry a higher risk for a number of adverse events, including sedation, confusion, urinary retention, cardiovascular and gastrointestinal issues [15].

Vortioxetine is a novel antidepressant, licensed for the treatment of depression in 2013 by FDA and EMA [16, 17]. Vortioxetine is an antagonist to 5-HT3, 5-HT1D and 5-HT7 receptors, a partial agonist to the 5-HT1B receptor and a 5-HT1A receptor agonist [18]. Its mechanism of action is not fully understood yet, but it is likely to be related with both a direct modulation of the serotonergic receptor activity and an inhibition of the serotonin transporter. Despite similarities with SSRIs, its pharmacological profile is claimed to be novel, and it is classified among “other antidepressants” by the World Health Organization (WHO) ATC/DDD Index 2018 [19]. Vortioxetine has similar pharmacokinetic properties in young and older adults [16], and existing data suggest it should not adversely affect psychomotor or cognitive performance, wakefulness, body weight, and electrocardiogram parameters [20, 21]. Further, possible, beneficial effects on cognition emerged from three randomized trials in participants with cognitive impairment [22]. A recent Cochrane systematic review, which included 15 randomized trials (7746 participants), showed vortioxetine to be effective compared to
placebo, while no significant differences emerged between vortioxetine and SNRIs as a class, in terms of both efficacy and tolerability [23]. The review did not include any study comparing vortioxetine with the SSRIs, but a recent network meta-analysis showed that vortioxetine is well tolerated and effective when indirectly compared to SSRIs [8]. Moreover, in two recent randomized trials, vortioxetine did not show significant differences on both mood and cognitive performance when compared to paroxetine [24] and escitalopram [25], respectively. The only available trial conducted in the elderly reported vortioxetine as more effective than placebo in terms of responders (301 participants, relative risk 1.49, 95% CI 1.14 to 1.95), while no differences emerged in terms of tolerability [26].

Aims of the study

The study will assess if, under real-world clinical circumstances, vortioxetine is better tolerated as compared with the SSRIs considered as a group in elderly participants with depression. In addition to tolerability, as secondary outcomes the study will assess acceptability, overall mortality, self-harm and suicide, adverse events, improvement of depressive symptoms, quality of life, and cognitive performance.

METHODS AND ANALYSIS

This protocol has been reported accordingly to the SPIRIT statements requirements. The complete SPIRIT checklist is available as an additional file and in the table at the end of the manuscript (additional file1).

Study design overview

The VESPA (Vortioxetine in the Elderly vs SSRIs: A Pragmatic Assessment) study is a randomized, parallel-group, multicentre, open-label, pragmatic, superiority trial. Over a 12-month recruitment period, psychiatrists from thirteen Italian Psychiatric Services will consecutively enrol in- and outpatients aged 65 or more suffering from an episode of major
depression and requiring treatment with an antidepressant. Participants will be randomly allocated to vortioxetine or to one of the SSRIs. Apart from treatment allocation, clinicians and patients will be free of increasing or decreasing the dose according to clinical status and circumstances, as well as of stopping or continuing treatment as clinically indicated. Similarly, the use of concomitant medications during the study will be allowed according to clinical status and circumstances. Routine care outside the trial will continue as usual. During the study, participants will be seen as often as clinically indicated with no extra visits required for the trial. The only requirement will be follow-up visits at one, three, and six months of follow-up (Fig. 1).

As a consequence of these pragmatic characteristics oriented to resemble clinical practice as much as possible, both patients and clinicians will not be blind to pharmacological treatments provided during the trial. Blinding will be applied to outcome assessors and statisticians performing the analyses. The study has been designed according to the principles described in the CONSORT statement (extended version for pragmatic trials) [27] and in agreement with the SPIRIT 2013 statement [28] (see Appendix 1). The study is financially supported by the Italian Medicines Agency (AIFA - Agenzia Italiana del Farmaco) and has already been approved by the Ethics Committee for Clinical Research of Verona and Rovigo (Comitato Etico per la Sperimentazione Clinica delle Province di Verona e Rovigo) (prot. n. 61211 of the 19/09/2018; Protocol version n. 1.5 of the 09/06/2018).

Assessment of pragmatism

To quantify the level of pragmatism of our study, we employed the pragmatic-explanatory continuum indicator summary-2 (PRECIS-2) [29]. This is a validated tool, developed to help investigators make design decisions consistent with the intended purpose of their trial. It explores nine domains (eligibility criteria, recruitment, setting, organisation, flexibility (delivery), flexibility (adherence), follow-up, primary outcome, and primary analysis), for each
of which a score from 1 (very explanatory) to 5 (very pragmatic) is provided. The result is graphically summarized in Fig. 2.

Reasons for the scoring are reported in Table 1. A routine use of the PRECIS-2 tool when submitting RCT protocols to funders, research ethics committees and peer-reviewed journals, has been growingly recommended, considering that not all RCTs self-labelled as "pragmatic" or "naturalistic" are actually pragmatic. This process can also help understand the extent to which trial results may be relevant to real-world practice [30].

Table 1. Scoring of PRECIS-2 tool. PRECIS 5-point Likert Scale score: (1) Very Explanatory; (2) Rather Explanatory; (3) Equally Pragmatic/Explanatory; (4) Rather Pragmatic; (5) Very Pragmatic.
| Items                                                                 | Score | Rationale                                                                                                                                                                                                 |
|----------------------------------------------------------------------|-------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Eligibility - to what extent are the participants in the trial similar to those who would receive this intervention if it was part of usual care | 4     | Target population: Elderly with depression. Inclusion criteria are wide. No exclusion criteria will be applied in terms of setting of recruitment, severity of depression, past use of psychotropic drugs, current use of benzodiazepines, number and severity of medical comorbidities, and multiple pharmacotherapy. Diagnosis are based on clinical judgment (guided by DSM-5 criteria), as it is in usual practice. Nevertheless investigator and patient have to agree to discontinue any current antidepressant, second generation antipsychotic, or lithium. |
| Recruitment - how much extra effort is made to recruit participants over and above what that would be used in the usual care setting to engage with patients? | 5     | Participants will be recruited without extra efforts. They will be recruited during usual appointments and/or visits.                                                                                      |
| Setting - how different is the setting of the trial and the usual care setting? | 4     | The study is multicenter, based in more than 10 psychiatric centers of the National Health System in Italy with a University center.                                                                    |
| Organisation - how different are the resources, provider expertise and the organisation of care delivery in the intervention arm of the trial and those available in usual care? | 4     | We will use usual staff and resources, but some extra resources will be necessary to hire researchers for the study.                                                                                     |
| Flexibility (delivery) - how different is the flexibility in how the intervention is delivered and the flexibility likely in usual care? | 5     | The intervention is flexible, similar to usual care.                                                                                                                                                    |
| Flexibility (adherence) - how different is the flexibility in how participants must adhere to the intervention and the flexibility likely in usual care? | 4     | No extra measures. Participants will be free to assume the intervention or drop it, but drugs will be prescribed and given to the participants during visits. This is different from usual care (patients have a prescription and go to the pharmacy to buy drugs). |
| Follow-up - how different is the intensity of measurement and follow-up of participants in the trial and the likely follow-up in usual care? | 4     | The primary outcome will be assessed after 1, 3 and 6 months, as it is usually done in everyday practice. Six months represent a clinically sound time frame for assessing the overall tolerability of medications, including both acute, short-term and medium-long-term effects. Nevertheless, visits could be longer than usual to assess all the scales and long-term effects and adverse events could occur after 6 months. |
| Primary outcome - to what extent is the trial's primary outcome relevant to participants? | 5     | Primary outcome is relevant to participants and policy makers.                                                                                                                                          |
| Primary analysis - to what extent are all data included in the analysis of the primary outcome? | 5     | The Intention to Treat (ITT) population will consist of all randomized patients. This ITT population will be used for the analysis of both primary and secondary outcomes. Missing values in rating scales will be imputed using the Last Observation Carried forward (LOCF) approach. |

 Participants
The following inclusion criteria will be applied:

a. The participant is 65 years old or above;
b. The participant is willing to participate by signing an informed consent form;
c. The participant is suffering from an episode of major depression, based on clinical judgment (guided by DSM-5 criteria);
d. Treatment with an antidepressant is appropriate, based on clinical judgment;
e. There is agreement between investigator and participant to discontinue any of the following concomitant drugs: antidepressant, second generation antipsychotic, or lithium. All other concomitant medications are allowed;
f. Uncertainty about which trial treatment would be best for the participant.

Participants will be excluded in case of:

a. Dementia, of any type and stage, as formally diagnosed by a specialist (geriatrician, neurologist, or others);
b. Diagnosis of schizophrenia or bipolar disorder;
c. Clinical conditions or treatments that contraindicate the use of oral vortioxetine or SSRIs, according to clinical/medical judgment (for example conditions or treatments that increase risk of bleeding, seizures, serotonergic syndrome, hyponatraemia, etc.).

All medications will be prescribed according to routine clinical practice, in compliance with the Summary of Product Characteristics (SPC) registered in the AIFA databank (https://farmaci.agenziafarmaco.gov.it/bancadatifarmaci/home).

No exclusion criteria will be applied in terms of setting of recruitment, severity of depression, past use of psychotropic drugs, current use of benzodiazepines (as long as SPC indications are respected), number and severity of medical comorbidities, and multiple pharmacotherapy.

Such criteria will select participants similar to those who require antidepressant treatment under usual care, including patients with multiple medical comorbidities. The recruitment will
be pragmatic, as participants will be selected among people attending inpatient and outpatient community services. There will not be overt recruitment effort. Also, allowing different recruitment settings, having multiple sites of recruitment, and selecting patients similar to those who are treated in every day clinical practice, will increase the generalizability of trial results. To control for a potential risk of excessive heterogeneity between centres, the randomization will be stratified by centre. According to these features, the PRECIS-2 “setting” domain has been evaluated as pragmatic.

Interventions

Patients will be randomized to either vortioxetine or one of the SSRIs. Doctors will be free to choose which SSRIs is more appropriate among those marketed in Italy and commonly used in clinical practice in the elderly (sertraline, citalopram, escitalopram, paroxetine, fluoxetine, fluvoxamine). A flexible dosing schedule, within the licensed dose range and in line with the summary of product characteristics (SPC), will be suggested (Table 2) in order to resemble clinical practice as much as possible.

Table 2. Treatments and dosing schedule
| Medication | Licensed dose range in the elderly | Notes from the registered Summary of Product Characteristics |
|------------|----------------------------------|-------------------------------------------------------------|
| vortioxetine | 5–20 mg/day | The minimum effective dose of 5 mg vortioxetine once daily should always be used as an initial dose for participants aged ≥ 65 years. Caution should be exerted when prescribing to elderly participants at doses above 10 mg vortioxetine once daily. |
| sertraline | 50–200 mg/day | Caution is required in the elderly, because these patients may be at greater risk of hyponatraemia. |
| paroxetine | 20–40 mg/day | In the elderly, increased plasma concentrations of paroxetine have been reported, however within the range observed in younger subjects. The treatment should start at the same doses used in adults. |
| citalopram | 10–20 mg/day | In the elderly, half of the dose range prescribed in adults is required. |
| escitalopram | 5–10 mg/day | In the elderly, half of the dose range prescribed in adults is required. |
| fluoxetine | 20–60 mg/day | Caution is required when the dose is increased in the elderly, and generally the daily dose should not be above 40 mg/day. The maximum recommended dose is 60 mg/day. |
| fluvoxamine | 100–300 mg/day | In elderly participants, titration should be slower and the dosage should always be established with caution. |

Formulation choice (tablets versus drops) will be made by clinicians and participants following everyday practice, and no measures will be implemented to optimise treatment adherence.

According to the PRECIS-2 “flexibility-delivery” and “flexibility-adherence” domains, treatment delivery has been rated as pragmatic, although a full score of 5 could not be reached as we were formally required to follow the EU pharmacovigilance regulation [31, 32].

Outcome measures

The number of participants withdrawing from allocated treatment due to adverse events at the end of the study (6 months) will represent the primary outcome. This measure may be considered a pragmatic proxy of tolerability [33] as it occurs when adverse events actually reach an unbearable burden, as perceived by patients and/or relatives and/or carers and/or clinicians. Antidepressant treatment will be considered withdrawn due to adverse effects when the drug is stopped for more than two consecutive weeks following the occurrence of any
adverse event, based on clinical judgment and/or as reported by participants. Participants will be additionally evaluated after also one and three months from randomization, collecting relevant clinical information and assessing scales, as showed in table 3. Side effects responsible for treatment withdrawal, and their severity, will be recorded the follow-up form and an ad hoc form for Severe Adverse Events (SAE).

Secondary outcomes will include:

1. acceptability: withdrawals from allocated treatment due to any cause (this outcome measure will include withdrawals for side-effects plus withdrawals for any other issues);
2. overall mortality;
3. any episode of deliberate self-harm;
4. suicide mortality;
5. adverse events, measured as the mean change in scores at the Antidepressant Side-Effect Checklist (ASEC) [34] at each time point. ASEC is a validated rating scale measuring the occurrence and severity of 21 antidepressant adverse events;
6. response to treatment, defined as a reduction of at least 50% of the baseline score of the Montgomery-Åsberg Depression Rating Scale (MADRS) [35] at each time point. MADRS is a validated, ten-item questionnaire for assessing the severity of depression;
7. efficacy, measured as mean change scores at MADRS at each time point;
8. quality of life, measured as mean change scores of the self-administered scale EQ-5D, [36], at each time point. EQ-5D explores five areas, including mobility, self-care, usual activities, pain/discomfort, anxiety/depression, and assesses the overall subjective perception of health with an analogic scale;
9. cognitive performance, measured as mean change scores of the Short Blessed Scale (SBT) [37], at each time point. SBT is a validated, six-item weighted instrument, originally designed to identify dementia, which assesses orientation, registration, and attention.
Rating scales to assess the secondary outcomes will be administered by blind assessors at one, two and three months after randomization. In addition, the Charlson Age-Comorbidity Index (CACI) [38] will be employed. This is a validated rating scale used to evaluate the degree of medical comorbidity, and to predict the 10-year survival in participants with multiple comorbidities. All study tools and phases are shown in Table 3.

**Table 3. Study phases and tools**

| Procedures and tools        | T0 Enrolment phase (duration: 12 months) | T1 (1 month) | T2 (3 months) | T3 (6 months) |
|-----------------------------|------------------------------------------|--------------|---------------|---------------|
| Review of criteria for inclusion in the study | X                                        |              |               |               |
| Informed consent document signed | X                                        |              |               |               |
| Randomization (allocation to treatment and number assigned) | X                                        |              |               |               |
| Recruitment Form            | X                                        | X            | X             | X             |
| ASEC                        | X                                        | X            | X             | X             |
| MADRS                       | X                                        | X            | X             | X             |
| EQ-5D                       | X                                        | X            | X             | X             |
| CACI                        | X                                        | X            | X             | X             |
| SBT                         | X                                        | X            | X             | X             |
| Follow-up form              | X                                        | X            | X             |               |
| Severe Adverse Event (SAE) Form | ↓ ↓ any time ◊ ◊                     |              |               |               |

**Safety**

The VESPA study will operatively employ the definitions endorsed by the EC Directive 2001/20/EC,[39]. As soon as a severe adverse event occurs, an ad hoc form for Severe Adverse Events (SAE) will be filled in and forwarded to the coordinating centre (University of Verona), in accordance with the EU regulation about pharmacovigilance in clinical research [31]. If, for any reasons, the disadvantages of participation will appear to be significantly greater than foreseen, the Principal Investigator of the site will inform trial participants and the bodies providing ethical oversight.

Considering that the study medications are already in the Italian market, and considering that they will be prescribed for licensed indications without altering clinical practice, the VESPA study has not appointed an ad hoc data safety and monitoring committee.
Randomization

Participants will be randomly assigned to vortioxetine or SSRIs with an allocation ratio of 1:1. A centralized web-based randomization procedure will be employed to guarantee the concealment of allocation. The trial biostatistician will prepare the sequence of treatments randomly permuted in blocks of constant size. The site investigators will not know the block size. Allocation will be stratified by recruiting centre. By using the web-based application RedCap [40], investigators will be able to screen participants for inclusion, administer instruments maintaining the blindness to treatment allocation, and randomize them.

Data management

At baseline, before randomization, and after one, three and six months, a number of socio-demographic and clinical information will be collected, along with the administration of the above-mentioned validated rating scales (MADRS, EQ-5D, CACI, SBT, ASEC). All data on other medications will be registered at every visit. The ASEC scale will be administered only during follow-up.

All study data will be collected with RedCap and digitally stored by the Istituto di Ricerche Farmacologiche Mario Negri IRCCS, a not-for-profit biomedical research organization based in Milan (Italy), where also the statistical analysis will be performed. RedCap will allow an immediate data validation at the moment of data collection. Moreover, a set of electronic and manual edit checks will be performed. The local coordinator of each recruiting centre will store and safely preserve hard copy documents (signed informed consent and self-administered questionnaires) for at least 7 years after the end of the study, according to the Italian law. At the end of the study the full dataset will be made available upon motivated request as a spreadsheet file in an online repository (e.g. Dryad Digital Repository). This is in line with FAIR principles [41], aimed at enhancing the accessibility and reutilization of novel research data. The accuracy and completeness of data collection will be monitored by site visits. At least one
visit for each recruiting centre is planned. Furthermore, auditing will be also carried out remotely, as the data manager of the study will be able to regularly check the trial dataset through the web application RedCap.

Power analysis

Considering the differential rate of withdrawals due to adverse events between SSRIs and vortioxetine on the basis of a meta-analysis of antidepressants for older people [9] and of three clinical trials of vortioxetine in older patients with depression [21, 26, 42] we expect the vortioxetine group to show a clinically significant advantage by reducing this rate from about 17% [9] to about 5% [21, 26, 42]. A sample size of 276 participants (138 in each group) achieves 90% power to detect a difference of 12% between the two withdrawal proportions in favour of vortioxetine. The test statistics will be the two-sided Z test with pooled variance. The significance level of the test is targeted at 5%. On the basis of the above-mentioned studies, we can assume that about 23% of the participants could be lost within 6 months (the mean of the total dropout rates of vortioxetine and SSRI studies in the elderly). Therefore 358 participants (179 in each group) will be enrolled in order to obtain at least 276 evaluable subjects. The sample size calculation was performed according to the methodology described by Pocock [43].

Statistical Analysis

According to the pragmatic principle of intention-to-treat (ITT), efforts will be made to follow each participant until the end of the study. The ITT population will consist of all randomized participants, and will be used for the analysis of both primary and secondary outcomes. The absolute risk of the primary outcome will be calculated on the ITT population. Subjects with missing primary outcome data will be allocated to the worst outcome. When possible, in addition to the primary analysis, appropriate statistical methods will adjust for the potential confounding effect of prognostic factors (sex, age, living condition, severity of comorbid
medical conditions, previous psychiatric history, MADRS score at baseline). Missing rating scales scores will be imputed using the Last Observation Carried forward (LOCF) approach: ratings will be carried forward from the last available assessment to the 6-month follow-up assessment. As a secondary analysis, missing scores will be imputed following a multiple imputation approach [44].

In order to check the results of the ITT approach, though for confirmatory purposes only, the primary outcome will also be analysed using a per-protocol (PP) approach. According to the PP approach, analysis will be restricted to subjects with primary outcome assessment available at six-months. Subjects withdrawing for reasons not related to adverse effects will be excluded from the analysis.

The proportion of participants withdrawing from the study due to adverse events within 6 months of follow-up will be compared between the two groups of treatment using a logistic regression with centre (random variable) as a covariate. A multivariable analysis (secondary analysis) will be performed through a Poisson regression model with a robust error variance, given that this procedure allows to estimate relative risks directly [45].

For dichotomous secondary outcomes, the proportion of participants withdrawing from the study due to adverse events within 6 months will be compared between the two groups of treatment using a logistic regression with centre (random variable) as a covariate. When possible, a multivariable analysis will be performed through a Poisson regression model with a robust error variance. For continuous secondary outcomes, the 6-month estimate will be compared between the two groups of treatment with an analysis of covariance with baseline value as an additional covariate, or with Mann-Whitney test on changes, according to the variable’s distribution. Same outcomes will be studied using linear mixed models taking into account all assessments to evaluate the rate of change with shorter repeated evaluations and no need of missing imputation. Further, score changes in subscales will be evaluated in order
to detect possible specific treatment-related side-effects.

A Cox proportional hazard model will be used to explore time to treatment withdrawal due to adverse events (secondary analysis). The proportional hazard assumption of the effects will be tested.

Adverse events will be tabulated. Nominal value for statistical significance will be set at 0.05, two-tailed. A specific Statistical Analysis Protocol will be produced and made publicly available before the inclusion of the last participant. All analyses will be performed using STATA [46], release 15 or higher.

ETHICS AND DISSEMINATION

This study will be conducted according to globally accepted standards of good clinical practice, as defined in the ICH E6 Guideline for Good Clinical Practice, 1 May 1996, in agreement with the Declaration of Helsinki [47] and in keeping with local regulations. The recruiting investigators will obtain informed consent. All participants will be informed about the study procedures and aims, both verbally and by written documentation. The subject’s consent will be confirmed by the personally dated signature of the subject and by the personally dated signature of the person conducting the informed consent discussion.

Participants can withdraw from the study at any time without further explanation or any negative consequences. Participants’ data will be managed and safeguarded in accordance with the European Data Protection Regulation 2016/679 [48]. The highly pragmatic design will minimize the time deduction to ordinary clinical practice. An Ethics Advisory Board (EAB) will indirectly supervise the processes of recruitment, informed consent procedures, and data management (protection and privacy), taking into due account the vulnerability of the population. Once the final report will be available, the study results will be extensively disseminated to the international scientific community in the form of peer-reviewed journal
articles, giving preference to open-access journals.

The study is financially supported by the AlFA and has already been approved by the Ethics Committee for Clinical Research of Verona and Rovigo (Comitato Etico per la Sperimentazione Clinica delle Province di Verona e Rovigo) (prot. n. 61211 of the 19/09/2018; Protocol version n. 1.5 of the 09/06/2018).

Discussion

The design of this study aims at achieving a high level of pragmatism. This approach will allow to minimize the risk of selection bias (particularly relevant when assessing frail populations such as the elderly, often excluded from experimental research), to resemble routine clinical procedures as much as possible, and therefore to maximize the external validity and generalizability of results [49]. Firstly, participants will be enrolled on the basis of the need for an antidepressant prescription because of a depressive episode. No formal diagnostic assessment will be performed, as happens in clinical practice. No limitations to the recruitment setting will be applied. Rating scales will be easy to administer and of relatively short duration, in order not to substantially alter clinical practice. Secondly, a web-based application will allow to simplify the process of recruitment, randomization, and collection of socio-demographic and clinical data, minimizing the time deducted from ordinary clinical practice. Thirdly, the comparison group will consist of participants receiving any of the SSRIs. We made this choice in order to avoid the possibility of selection bias, that is to avoid the systematic exclusion of participants who did not benefit from a specific SSRI in the past. Furthermore, flexible dosing schedule will be employed, according to clinical judgment, within the recommended therapeutic range.

Some limitations need to be outlined. Firstly, according to the current pharmacovigilance regulation of the European Union, medication boxes must be labelled and dispensed by the
hospital pharmacy. This deviates from ordinary practice, and may have an impact on adherence to medications. Secondly, in order to avoid the potential confounding effect of other psychotropic drugs, to be included in the trial patients have to discontinue any other antidepressant or second generation antipsychotic before random allocation, but after random allocation any concomitant medication will be allowed. Again, this choice aims at resembling everyday practice, as elderly patients are sometimes prescribed low doses of second generation antipsychotics or antidepressant (e.g. mirtazapine, amitriptyline, trazodone) for insomnia or for other symptoms (e.g. cachexia, cephalalgia, etc.).

Thirdly, the open-label design might be associated with a risk of performance bias. Theoretically, it may be possible that clinicians, being aware of the treatments received by participants, perform differently according to the allocated treatment arms, based on personal subjective judgments. For example, they may provide vortioxetine, or the control SSRI, at excessively low or high doses, altering this way the likelihood of dropping out from treatment because of side-effects or lack of efficacy. Although we cannot completely rule out this possibility, we note the following. First, as both treatment arms involve active antidepressants, it seems unlikely that doctors involved in the study, working in very diverse settings across Italy, share similar a-priori opinions and, based on these opinions, systematically favour or disfavour either vortioxetine or the control SSRIs. Second, any dose changes and any use of concomitant medicines, as well as any provision of additional non-pharmacological treatments, will be recorded, which is important to investigate if, apart from the study medications, the two groups were treated similarly. Third, blinded assessors will independently assess the presence and severity of adverse events using the ASEC, and this will allow an internal quality check of the accuracy of the primary outcome.

Considering the overall psychological, medical and economic burden of depression in the elderly, and the few available pharmacological alternatives for treating this population group,
the results of this study are likely to have a positive impact on everyday clinical practice. Furthermore, considering the pragmatic nature of the study, we expect that results will be immediately applicable to ordinary practice without requiring any specific training or implementation strategies. If the hypothesis of a better tolerability of vortioxetine is confirmed, this drug may become a reference first-line drug for the treatment of depression in the elderly. This, besides improving the overall psychological well-being and quality of life of elderly people with depression, might at the same time reduce hospitalizations for medical adverse events (such as falls, bleeding, hyponatraemia, QTc alterations), poor medical outcomes, and related health care costs. If, on the other hand, vortioxetine is not better tolerated than SSRIs, its place in the treatment of the elderly will be clearer, and the VESPA study results will be used to better inform clinical and policy practice.

Additionally, this study may have regulatory implications, considering that, currently, according to the EMA, “caution is advised when treating participants ≥ 65 years of age with doses higher than 10 mg vortioxetine once daily for which data are limited” [17, 18]. We expect that this statement may be reformulated in view of the study results: if vortioxetine is better tolerated than the SSRIs, by mentioning its favourable tolerability profile; if vortioxetine is less tolerated than the SSRIs, by further reinforcing the cautionary statement.

Abbreviations

selective serotonin reuptake inhibitor (SSRIs), Randomized controlled trial (RCT), tricyclic antidepressants (TCAs), serotonin and norepinephrine reuptake inhibitors (SNRIs), Food and Drug administration (FDA), European Medicine Agency (EMA), World Health Organization (WHO), Vortioxetine in the Elderly vs SSRIs: A Pragmatic Assessment (VESPA), Italian Medicines Agency (AIFA - Agenzia Italiana del Farmaco), Pragmatic-explanatory continuum indicator summary-2 (PRECIS-2), Summary of Product Characteristics (SPC), Severe Adverse
Events (SAE), Antidepressant Side-Effect Checklist (ASEC), Montgomery-Åsberg Depression Rating Scale (MADRS), Short Blessed Scale (SBT), Charlson Age-Comorbidity Index (CACI), Intention-to-treat (ITT), Last Observation Carried forward (LOCF), per-protocol (PP), Ethics Advisory Board (EAB).

**Declarations**

**Trial Status:** protocol version 1.5; 09/06/2018. Recruitment started on February 2019 and it is ongoing. It is expected to end approximately on September 30th 2021.

**Ethics approval and consent to participate**

The protocol (version 1.5; 09/06/2018) has already been approved by the Ethics Committee for Clinical Research of Verona and Rovigo (approval reference number: Prot n. 61211 19/09/2018). All participants will sign a written informed consent form.

**Availability of data and materials**

At the end of the study the full dataset will be made available upon motivated request as a spreadsheet file in an online repository (e.g. Dryad Digital Repository). This is in line with FAIR principles [41], aimed at enhancing the accessibility and reutilization of novel research data.

**Competing interests**

The authors have no competing interests to disclose.

**Funding**

The study is funded by AIFA within the 2016 call for Independent Research on Drugs (Bando AIFA per la Ricerca Indipendente 2016); code: 2016-0234923. The study sponsor will have no role in study design; in the collection, management, analysis, and interpretation of data; in writing the report; and in the decision to submit the report for publication. The study sponsor has no ultimate authority over any of the listed activities.

**Consent to publication**
N/A. Not applicable.

Authors' contributions

All authors listed have made substantial contributions to the design of the study; contributed to draft and revising the manuscript, approving the final version to be published. All authors agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Designed the study: GO, CB, AB, BDA, MT; drafted the manuscript: GO, CB, AB, BDA, MT, CG; development and implementation on the online tool for data collection: IM; contributed to the design of the study and its in-field implementation via plenary meetings, revised and approved the manuscript: CG, AA, EA, CA, MA, FB, MB, PB, CC, GC, RC, SC, CCr, ADA, PDF, CDN, LG, LGr, GM, MN, DP, MP, AR, RR, LT, GT, EZ, FA, MR.

Acknowledgements

None.

References

1. GBD. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 2016;388(10053):1659-724 doi: 10.1016/s0140-6736(16)31679-8[published Online First: Epub Date]].

2. CDCP. Current depression among adults-United States, 2006 and 2008. Centers for Disease Control and Prevention Morbidity and mortality weekly report 2010;59(38):1229-35

3. Ames D. Depression among elderly residents of local-authority residential homes. Its nature and the efficacy of intervention. Br J Psychiatry 1990;156:667-75
4. Eden J. Institute of medicine. The mental health and substance use workforce for older adults. In whose hands? Washington D.C.: National Academies Press., 2012. https://doi.org/10.17226/13400

5. Heisel MJG; Moore S L; Jackson F. et al. National Guidelines for Seniors’ Mental Health: The Assessment of Suicide Risk and Prevention of Suicide. Can Geriatr J 2006; 9(2):s65-s70

6. Steenland K, Karnes C, Seals R, et al. Late-life depression as a risk factor for mild cognitive impairment or Alzheimer's disease in 30 US Alzheimer's disease centers. J Alzheimers Dis 2012;31(2):265-75 doi: 10.3233/jad-2012-111922[published Online First: Epub Date]

7. Jiang W, Alexander J, Christopher E, et al. Relationship of depression to increased risk of mortality and rehospitalization in patients with congestive heart failure. Arch Intern Med 2001;161(15):1849-56

8. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet 2018;391(10128):1357-66 doi: 10.1016/s0140-6736(17)32802-7[published Online First: Epub Date]

9. Mottram P, Wilson K, Strobl J. Antidepressants for depressed elderly. Cochrane Database Syst Rev 2006 (1): Cd003491 doi: 10.1002/14651858.CD003491.pub2 [published Online First: Epub Date]

10. National Institute for Health and Care Excellence. Depression in adults: recognition and management [Internet]. [London]: NICE; 2009 [updated 2016 Apr; cited 2016 Dec 16]. (Clinical guideline [CG90]). Available from: https://www.nice.org.uk/guidance/cg90

11. Avasthi A, Grover S. Clinical Practice Guidelines for Management of Depression in Elderly. Indian J Soc Psychiatry 2018;60(Suppl 3): S341-s62 doi: 10.4103/0019-5545.224474
Taylor WD. Should antidepressant medication be used in the elderly? Expert Rev Neurother 2015;15(9):961-3 doi: 10.1586/14737175.2015.1070671 [published Online First: Epub Date]].

Sultana J, Spina E, Trifiro G. Antidepressant use in the elderly: the role of pharmacodynamics and pharmacokinetics in drug safety. Expert Opin Drug Metab Toxicol 2015;11(6):883-92 doi: 10.1517/17425255.2015.1021684 [published Online First: Epub Date]].

de Abajo FJ. Effects of selective serotonin reuptake inhibitors on platelet function: mechanisms, clinical outcomes and implications for use in elderly patients. Drugs Aging 2011;28(5):345-67 doi: 10.2165/11589340-000000000-00000 [published Online First: Epub Date]].

Hickie IB. Antidepressants in elderly people. BMJ 2011;343:d4660 doi: 10.1136/bmj.d4660 [published Online First: Epub Date]].

FDA. Drug Approval Package. Brintellix (vortioxetine) Tablets. Company: Takeda Pharmaceuticals USA, Inc.; Application No.: 204447. Food and Drug Adminstration. 2013. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204447Orig1s000TOC.cfm (accessed 13 May 2019)

EMA. Brintellix. Vortioxetine. Procedure No. EMEA/H/C/002717. Applicant: H. Lundbeck A/S. Assessment report for an initial marketing authorisation application. European Medicines Agency. 2013. https://www.ema.europa.eu/en/documents/assessment-report/brintellix-epar-public-assessment-report_en.pdf

EMA. Brintellix : EPAR - Product Information. Brintellix -EMEA/H/C/002717 -IB/0020. European Medicines Agency 2014.
http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_
Methodology WCCfDS. ATC classification index with DDDs. Oslo, Norway, 2019. 
https://www.whocc.no/atc_ddd_index/

Kelliny M, Croarkin PE, Moore KM, et al. Profile of vortioxetine in the treatment of major depressive disorder: an overview of the primary and secondary literature. Ther Clin Risk Manag 2015;11:1193-212 doi: 10.2147/tcrm.S55313[published Online First: Epub Date]].

McIntyre RS, Lophaven S, Olsen CK. A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults. Int J Neuropsychopharmacol 2014;17(10):1557-67 doi: 10.1017/s1461145714000546[published Online First: Epub Date]].

Miskowiak KW, Ott CV, Petersen JZ, et al. Systematic review of randomized controlled trials of candidate treatments for cognitive impairment in depression and methodological challenges in the field. European neuropsychopharmacology: the journal of the Eur Neuropsychopharmacol 2016;26(12):1845-67 doi: 10.1016/j.euroneuro.2016.09.641[published Online First: Epub Date]].

Koesters M, Ostuzzi G, Guaiana G, et al. Vortioxetine for depression in adults. The Cochrane Database Syst Rev 2017;7: Cd011520 doi: 10.1002/14651858.CD011520.pub2[published Online First: Epub Date]].

Baune BT, Sluth LB, Olsen CK. The effects of vortioxetine on cognitive performance in working patients with major depressive disorder: A short-term, randomized, double-blind, exploratory study. J Affect Disord 2018;229:421-28 doi: 10.1016/j.jad.2017.12.056[published Online First: Epub Date]].

Vieta E, Sluth LB, Olsen CK. The effects of vortioxetine on cognitive dysfunction in patients with inadequate response to current antidepressants in major depressive disorder: A short-term, randomized, double-blind, exploratory study versus escitalopram.
26. Katona C, Hansen T, Olsen CK. A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder. Int Clin Psychopharmacol 2012;27(4):215-23 doi: 10.1097/YIC.0b013e3283542457 [published Online First: Epub Date].

27. Zwarenstein M, Treweek S, Gagnier JJ, et al. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ 2008;337:a2390 doi: 10.1136/bmj.a2390[published Online First: Epub Date].

28. Chan AW, Tetzlaff JM, Altman DG, et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med 2013;158(3):200-7 doi: 10.7326/0003-4819-158-3-201302050-00583[published Online First: Epub Date].

29. Loudon K, Treweek S, Sullivan F, et al. The PRECIS-2 tool: designing trials that are fit for purpose. BMJ 2015;350:h2147 doi: 10.1136/bmj.h2147[published Online First: Epub Date].

30. Dal-Re R, Janiaud P, Ioannidis JPA. Real-world evidence: How pragmatic are randomized controlled trials labeled as pragmatic? BMC Med 2018;16(1):49 doi: 10.1186/s12916-018-1038-2[published Online First: Epub Date].

31. EU. DIRECTIVE 2010/84/EU OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 15 December 2010 amending, as regards pharmacovigilance, Directive 2001/83/EC on the Community code relating to medicinal products for human use. Official Journal of the European Communities 2010;348:74-99

32. EU. Communication from the Commission — Detailed guidance on the collection, verification and presentation of adverse event/reaction reports arising from clinical trials
on medicinal products for human use (‘CT-3’). Official Journal of the European Union 2011;2011/C(172):1-13

33. Barbui C, Furukawa TA, Cipriani A. Effectiveness of paroxetine in the treatment of acute major depression in adults: a systematic re-examination of published and unpublished data from randomized trials. CMAJ 2008;178(3):296-305 doi: 10.1503/cmaj.070693[published Online First: Epub Date]].

34. Uher R, Farmer A, Henigsberg N, et al. Adverse reactions to antidepressants. Br J Psychiatry 2009;195(3):202-10 doi: 10.1192/bjp.bp.108.061960[published Online First: Epub Date]].

35. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-9

36. EuroQol. EuroQol--a new facility for the measurement of health-related quality of life. Health Policy 1990;16(3):199-208

37. Katzman R, Brown T, Fuld P, et al. Validation of a short Orientation-Memory-Concentration Test of cognitive impairment. Am J Psychiatry 1983;140(6):734-9 doi: 10.1176/ajp.140.6.734[published Online First: Epub Date]].

38. Charlson M, Szatrowski TP, Peterson J, et al. Validation of a combined comorbidity index. J Clin Epidemiol 1994;47(11):1245-51

39. EU. Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use, 2001. https://ec.europa.eu/health/sites/health/files/files/eudralex/vol-1/dir_2001_20/dir_2001_20_en.pdf (accessed 13 May 2019)

40. Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap)--a
metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009;42(2):377-81 doi: 10.1016/j.jbi.2008.08.010 [published Online First: Epub Date]]

41. Wilkinson MD, Dumontier M, Aalbersberg IJ, et al. The FAIR Guiding Principles for scientific data management and stewardship. Sci Data 2016;3:160018 doi: 10.1038/sdata.2016.18 [published Online First: Epub Date]]

42. Mahableshwarkar AR, Zajecka J, Jacobson W, et al. A Randomized, Placebo-Controlled, Active-Reference, Double-Blind, Flexible-Dose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive Disorder. Neuropsychopharmacology 2016;41(12):2961 doi: 10.1038/npp.2016.181 [published Online First: Epub Date]]

43. Pocock SJ. Clinical trials. A practical approach. Chichester: Wiley, 1983.

44. Little RJ, D'Agostino R, Cohen ML, et al. The prevention and treatment of missing data in clinical trials. N Engl J Med 2012;367(14):1355-60 doi: 10.1056/NEJMsr1203730 [published Online First: Epub Date]]

45. Zou G. A modified poisson regression approach to prospective studies with binary data. Am J Epidemiol 2004;159(7):702-6

46. Stata Statistical Software: Release 15 [program]. College Station, TX: StataCorp LLC, 2017.

47. WMA. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. Jama 2013;310(20):2191-4 doi: 10.1001/jama.2013.281053 [published Online First: Epub Date]]

48. EU. REGULATION (EU) 2016/679 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 27 April 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data, and repealing Directive 95/46/EC (General Data Protection Regulation). Official Journal of the European Union 2016;119:1-
49. Ford I, Norrie J. Pragmatic Trials. N Engl J Med 2016;375(5):454-63 doi: 10.1056/NEJMra1510059 [published Online First: Epub Date].

Table 4

Due to technical limitations, Table 4 is provided in the Supplementary Files.

Figures
Figure 1

Study flow-chart. Legend: RF=recruitment form; FUF=follow-up form; MADRS=Montgomery-. 
Figure 2

Pragmatism wheel according to the PRECIS-2 tool

Supplementary Files

This is a list of supplementary files associated with the primary manuscript. Click to download.

Table 4.docx
Additional file 1.doc